Home › Trials › NCT06603844

New treatment for advanced solid tumors using CRB-601

A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of CRB-601, a Monoclonal Antibody Against Integrin avb8, in Patients With Advanced Solid Tumors

Phase1; Phase2 Interventional Corbus Pharmaceuticals Inc. · NCT06603844

This study is testing a new treatment called CRB-601 for people with advanced solid tumors that haven't improved with other therapies to see how safe and effective it is.

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Enrollment156 (estimated)
Ages18 Years and up
SexAll
SponsorCorbus Pharmaceuticals Inc. Industry-sponsored
Drugs / interventionsimmunotherapy
Locations26 sites (Birmingham, Alabama and 25 other locations)
Trial IDNCT06603844 on ClinicalTrials.gov

What this trial studies

This study evaluates the safety and effectiveness of CRB-601, a monoclonal antibody targeting the avb8 integrin protein, in patients with advanced solid tumors who have not responded to other treatments. The trial consists of three parts, including dose escalation and combination therapies with immunotherapy and immune-priming radiotherapy. Researchers will assess side effects, blood levels of CRB-601, and its impact on cancer progression. The goal is to determine the optimal dosing and treatment combinations for patients with specific tumor types.

Who should consider this trial

Good fit: Ideal candidates are patients with advanced solid tumors that have progressed after at least one line of therapy and express the avb8 integrin protein.

Not a fit: Patients with solid tumors that do not express the avb8 integrin protein or those with certain severe comorbidities may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with advanced solid tumors who have limited treatment choices.

How similar studies have performed: While this approach is novel, similar studies targeting specific tumor markers have shown promise in the past.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Confirmed diagnosis of select locally advanced or metastatic solid tumors that have progressed after at least one line of therapy or have no other standard therapy with proven clinical benefit available.
* Measurable disease on imaging as assessed by RECIST 1.1 Eastern Cooperative Oncology Group (ECOG) performance status (PS) greater or equal to 2.
* Life expectancy of more than 12 weeks.
* Adequate hematologic and end-organ function.

Exclusion Criteria:

* History of solid tumor malignancies other than the disease under study within 3 years of study enrollment
* History of and/or current cardiovascular events or conditions
* Chronic severe liver disease or liver cirrhosis
* Systemic autoimmune disease
* Active thrombophlebitis, thromboembolism or hypercoagulability states or uncontrolled bleeding or diabetes.
* Interstitial lung disease within 6 months of study enrollment.
* Active or persistent infection
* Other conditions that in the opinion of the Investigator would compromise the outcomes of the study.

Where this trial is running

Birmingham, Alabama and 25 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Solid Tumor
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.